## DMD#79244 Supplemental data

## Journal: Drug Metabolism and Disposition

# Liver zonation index of drug transporter and metabolizing enzyme protein expressions in mouse liver acinus.

Masanori Tachikawa, Yuna Sumiyoshiya, Daisuke Saigusa, Kazunari Sasaki, Michitoshi Watanabe, Yasuo Uchida, Tetsuya Terasaki

## **Supplemental Methods**

## Sulforhodamine101 (SR-101) uptake by mouse Oatp2b1-overexpressing HEK293 cells

HEK293 cells transiently expressing Oatp2b1 were generated by transfection of myc-DDK-tagged open reading frame of mouse Oatp2b1 inserted in the pCMV6 vector (OriGene Technologies, Rockville, MD), respectively. The transfection was performed using Lipofectamine<sup>TM</sup> 2000 and Opti-MEM I medium (Invitrogen) according to the manufacturer's protocol. Briefly, the cells were seeded at 90% confluence in 24-well plates using antibiotic-free medium. The complex of the vector and lipofectamine was incubated with the cells for 6 h, and then the cells were cultured in normal culture medium for 24 hrs. For uptake study, the cells were washed with normal extracellular fluid (ECF) buffer (122 mM NaCl, 25 mM NaHCO3, 3 mM KCl, 0.4 mM K<sub>2</sub>HPO<sub>4</sub>, 10 mM glucose, 1.4 mM CaCl<sub>2</sub>, 1.2 mM MgSO<sub>4</sub> and 10 mM HEPES, pH 7.4). Uptake was initiated by applying 300 μL normal ECF buffer containing 1 μM SR101 at 37°C. At 20 min, the solution was removed to terminate uptake, and the cells were washed in ice-cold normal ECF buffer. Images were taken with a fluorescence microscope (Fluoview, Olympus, Tokyo, Japan). The cells were then homogenized in distilled water using a sonicator. The homogenate was centrifuged at 21,600xg for 5 min at 4°C and the supernatant was collected. The cell-associated fluorescence was measured with a fluorescence detector (Fluoroscan Acent FL, Thermo Fisher Scientific, Waltham, MA). The accumulation of SR-101 in the cells was expressed as the cell-associated fluorescence per well.

# DMD#79244 Supplemental Table S1 Target peptide sequences and selected/multiple reaction monitoring

| Molecule                  | T                       | SRM/MRM transitions (m/z) |          |                      |          |          |  |  |
|---------------------------|-------------------------|---------------------------|----------|----------------------|----------|----------|--|--|
| wioiecule                 | rarget peptide sequence | Q1                        | Q3-1     | Q3-2                 | Q3-3     | Q3-4     |  |  |
| Slc21a7/Oatp1a5           | SENSPLYIGILESGK         | 803.9                     | 1189.683 | 816.4828             | 703.3987 | 533.2931 |  |  |
|                           | SENSPLYIGIL*ESGK        | 807.4                     | 1196.7   | 823.5                | 710.4159 | 540.3103 |  |  |
| Slc38a4/Ata3              | TSVITLLFPR              | 573.8                     | 859.5402 | 746.4561             | 532.3243 | 419.2402 |  |  |
|                           | TSVITLLF <b>P</b> *R    | 576.9                     | 865.554  | 752.4699             | 538.3381 | 425.254  |  |  |
|                           | LLFGPLPDLDGK            | 642.9                     | 1058.552 | 911.4833             | 757.4092 | 432.2454 |  |  |
| Abca2                     | LLFGPLPD <b>L</b> *DGK  | 646.4                     | 1065.569 | 918.5004             | 764.4264 | 439.2624 |  |  |
|                           | VFQVGNK                 | 396.2                     | 692.3727 | 545.3043             | 318.1773 | 417.2457 |  |  |
| Abca3                     | VFQ <b>V</b> *GNK       | 399.2                     | 698.3864 | 551.3181             | 318.1773 | 423.2594 |  |  |
|                           | WIAEPAR                 | 421.7                     | 656.3727 | 543.2886             | 343.2089 | 175.119  |  |  |
| Abca4                     | WIAEPA*R                | 423.7                     | 660.3798 | 547.2957             | 347.216  | 175.119  |  |  |
|                           | NAVVPIK                 | 370.7                     | 357.2498 | 555.3866             | 456.3182 | 626.4237 |  |  |
| Abca5                     | NAVVP <b>I</b> *K       | 374.2                     | 364.267  | 562.4038             | 463.3354 | 633.4409 |  |  |
|                           | LFPQAAR                 | 401.7                     | 542.3046 | 445.2518             | 317.1932 | 689.373  |  |  |
| Abca6, 8a, 9              | LFPQAA*R                | 403.7                     | 546.3117 | 449.2589             | 321.2003 | 693.3801 |  |  |
|                           | OFOSPLR                 | 438.2                     | 385.2559 | 600.3464             | 472.2879 | 747.4149 |  |  |
| Abca7                     | OFOSPL*R                | 441.7                     | 392.2731 | 607.3637             | 479.3051 | 754.4321 |  |  |
|                           | DLTLDVYK                | 483.8                     | 738.4033 | 637.3556             | 524.2715 | 310.1762 |  |  |
| Abca8a                    | DLTLD <b>V</b> *YK      | 486.8                     | 744.4171 | 643.3694             | 530.2853 | 310.1762 |  |  |
|                           | LFPOASR                 | 409.7                     | 705.3679 | 558.2995             | 461.2467 | 333.1881 |  |  |
| Abca8b                    | LFPOA*SR                | 411.7                     | 709.375  | 562.3066             | 465.2538 | 337.1952 |  |  |
|                           | LLPOFEL                 | 421.2                     | 227 1757 | 615,2986             | 132,102  | 710 3723 |  |  |
| Abca9                     | LLP*OEEL                | 424.2                     | 227.1757 | 621.3124             | 132.102  | 716 3861 |  |  |
|                           | LLAIPIPDNR              | 561.3                     | 711 3784 | 501 2416             | 824 4626 | 614 3257 |  |  |
| Abca12                    | LLAIPI <b>P</b> *DNR    | 564.3                     | 717 3923 | 507 2554             | 830 4764 | 620 3395 |  |  |
|                           | NIVWDPOK                | 500.3                     | 487 2512 | 772 3989             | 673 3305 | 372 2243 |  |  |
| Abca13                    | NIVWD <b>P</b> *OK      | 503.3                     | 493 265  | 778 4127             | 679 3443 | 378 2381 |  |  |
|                           | IATEAIENIR              | 565.3                     | 531 2886 | 715 4098             | 644 3727 | 844 4524 |  |  |
| Abcb4 / mdr2              | IATEA*IENIR             | 567.3                     | 531.2000 | 719 4169             | 644 3727 | 848 4595 |  |  |
|                           | VI PNPALK               | 458.3                     | 620 3647 | 128 2869             | 542 3298 | 331 23/1 |  |  |
| Cyp1a2                    | VI PNPALK*              | 462.3                     | 620.3647 | 436 3011             | 550 344  | 339 2483 |  |  |
|                           | CYCVVESSCEP             | 402.3<br>570.3            | 781 3830 | 430.3011             | 330.344  | 535.2485 |  |  |
| Cyp2a5                    | GYGVVESSGER*            | 584.3                     | 701 3022 | 602 3238             | 377.1822 | 545 2554 |  |  |
|                           | NISOSETNESK             | 626.9                     | 1045 405 | 820 4042             | 7/2 2722 | 506 2020 |  |  |
| Cyp2c29                   | NISOSETNESK*            | 640.8                     | 1043.493 | 830.4043<br>828 4185 | 751 2965 | 604 2191 |  |  |
|                           | CTTUTNU SSALV           | 650.0                     | 822 4729 | 486 2026             | 046 5560 | 722 4251 |  |  |
| Cyp2d22                   | GTTLITNLSSALK           | 639.9                     | 055.4720 | 480.2920             | 940.3309 | 732.4231 |  |  |
|                           | GITLIINLSSAL <b>K</b> * | 463.9                     | 841.487  | 480.2920             | 954.5711 | 740.4393 |  |  |
| Ugt1a1                    | SLSFNSDR                | 463.2                     | 725.3212 | 038.2892             | 491.2208 | 201.1230 |  |  |
|                           | SESFISD <b>R</b> *      | 408.2                     | 735.3295 | 648.2975             | 501.2291 | 201.1230 |  |  |
| Ugt1a9                    | SFLIGSAK                | 419.7                     | 255.108  | 604.541              | 491.237  | 390.21   |  |  |
| -                         | SFLIGSAR*               | 424.7                     | 245.108  | 596.267              | 120.000  | 400.21   |  |  |
| Ugt2b5                    | GAAVALNIR               | 442.8                     | 200.103  | 586.367              | 129.066  | 299.171  |  |  |
|                           | GAAVALNIR*              | 447.8                     | 200.103  | 596.367              | 129.066  | 299.171  |  |  |
| Ugt2b36                   |                         | 514.3                     | 544.284  | 657.368              | 758.416  | 487.262  |  |  |
| -                         | TPATLGPNT <b>R</b> *    | 519.3                     | 554.284  | 667.368              | /68.416  | 497.262  |  |  |
| HMG-CoA reductase         | LAEPSSLQYLPYR           | 768.9                     | 1223.642 | 435.2351             | 839.4411 | 314.1713 |  |  |
|                           | LAEPSSLQYLPY <b>K</b> * | 7/3.9                     | 1233.65  | 445.2434             | 849.4494 | 314.1713 |  |  |
| NADPH-CPR                 | FAVFGLGNK               | 476.8                     | 635.3513 | 734.4197             | 488.2829 | 805.4568 |  |  |
|                           | FAVFGL*GNK              | 480.3                     | 642.3685 | 741.4369             | 495.3001 | 812.474  |  |  |
| FcRn                      | EQLFLEALK               | 545.8                     | 573.3606 | 460.2766             | 720.4291 | 833.5131 |  |  |
|                           | EQLFLEALK*              | 549.8                     | 581.3748 | 468.2908             | 728.4433 | 841.5273 |  |  |
| Glutamine synthetase (GS) | DIVEAHYR                | 501.8                     | 774.3893 | 675.3209             | 546.2783 | 387.6983 |  |  |
|                           | DIVEAHY <b>R</b> *      | 506.8                     | 784.3976 | 685.3292             | 556.2866 | 392.7024 |  |  |
| Actin                     | AGFAGDDAPR              | 488.7                     | 701.3213 | 630.2842             | 458.2358 | 343.2089 |  |  |
| Attil                     | AGFAGDDA <b>P</b> *R    | 491.7                     | 707.3351 | 636.298              | 464.2496 | 349.2227 |  |  |

## (SRM/MRM) transitions for quantification of each protein

Bold letters with asterisks indicate amino acid residues labeled with stable isotope (13C and 15N). Conditions of SRM/MRM analysis were optimized for high signal intensity following direct injection of peptide solution into the mass spectrometer through a turbo ion spray source. Theoretical m/z values of doubly charged ions of intact peptides (Q1) were assumed for precursor ions. Four singly charged fragment ions (Q3) were derived from each precursor ion.

|                       | Limit of quantification |          |  |  |  |
|-----------------------|-------------------------|----------|--|--|--|
| Alias                 | (fmol/mm <sup>2</sup> ) |          |  |  |  |
|                       | <b>SR101</b> (+)        | SR101(-) |  |  |  |
| Slc transporter       |                         |          |  |  |  |
| Slc2a1/Glut1          | 0.287                   | 0.309    |  |  |  |
| Slc6a2/Net            | 1.11                    | 1.10     |  |  |  |
| Slc7a5/Lat1           | 0.565                   | 0.551    |  |  |  |
| Slc16a7/Mct2          | 0.860                   | 0.872    |  |  |  |
| Slc21a2/Oatp2a1 (Pgt) | 1.94                    | 1.48     |  |  |  |
| Slc21a5/Oatp1a4       | 3.00                    | 4.11     |  |  |  |
| Slc21a7/Oatp1a5       | 2.41                    | 2.29     |  |  |  |
| Slc21a9/Oatp2b1       | 1.29                    | 1.24     |  |  |  |
| Slc21a11/Oatp3a1      | 1.43                    | 1.36     |  |  |  |
| Slc21a12/Oatp4a1      | 0.635                   | 0.604    |  |  |  |
| Slc21a13/Oatp1a6      | 2.21                    | 2.08     |  |  |  |
| Slc21a14/Oatp1c1      | 0.685                   | 0.649    |  |  |  |
| Slc21a17/Oatp17       | 1.03                    | 1.15     |  |  |  |
| Slc21a18/Oatp18       | 2.30                    | 2.23     |  |  |  |
| Slc38a4/Ata3          | 0.375                   | 0.402    |  |  |  |
| Slc47a1/Mate1         | 1.18                    | 1.14     |  |  |  |
| Abc transporter       |                         |          |  |  |  |
| Abcal                 | 0.448                   | 0.427    |  |  |  |
| Abca2                 | 1.15                    | 1.14     |  |  |  |
| Abca3                 | 0.332                   | 0.329    |  |  |  |
| Abca5                 | 0.315                   | 0.316    |  |  |  |
| Abca6, 8a, 9          | 0.839                   | 0.868    |  |  |  |
| Abca7                 | 0.323                   | 0.298    |  |  |  |
| Abca8a                | 1.47                    | 1.40     |  |  |  |
| Abca8b                | 0.445                   | 0.461    |  |  |  |
| Abca9                 | 0.487                   | 0.493    |  |  |  |
| Abca12                | 0.834                   | 0.853    |  |  |  |
| Abca13                | 0.547                   | 0.529    |  |  |  |
| Abcb1a/Mdr1a          | 0.425                   | 0.406    |  |  |  |
| Abcb1b/Mdr1b          | 0.566                   | 0.544    |  |  |  |
| Abcc3/Mrp3            | 0.677                   | 0.651    |  |  |  |
| Abcc5/Mrp5            | 0.220                   | 0.225    |  |  |  |
| Abcc12/Mrp9           | 0.503                   | 0.464    |  |  |  |
| Abcg8                 | 0.257                   | 0.264    |  |  |  |
| Enzyme                |                         |          |  |  |  |
| Cyp1a2                | 32.3                    | 32.1     |  |  |  |
| Cvp2a5                | 0.399                   | 0.385    |  |  |  |
| Ugt2b5                | 1.93                    | 1.82     |  |  |  |
| HMG-CoA reductase     | 0.620                   | 0 594    |  |  |  |

## DMD#79244 Supplemental Table S2 Molecules under the limit of quantification

## DMD#79244

Supplemental Table S3 Summery of the zonated expressions of transporters and metabolizing enzymes in peri-portal vein (PP) or peri-central vein (PC) regions of the liver in rodents

| Molecule        |         | Species                           | Method  | mRNA<br>Protein | Distribution<br>in PP and PC<br>regions   | Reference                           |
|-----------------|---------|-----------------------------------|---|-----------------|---|-------------------------------------|
| Slc transporter |         |                                   |   |                 |   |                                     |
| Slc10a1         | Ntcp    | Male<br>Sprague-<br>Dawley<br>Rat | Quantitative<br>PCR/Isolated<br>hepatocytes by ante- or<br>retrograde perfusion<br>with digitonin | mRNA            | PP=PC   | (Baier et<br>al., 2006)             |
|                 |         |                                   | Immunohistochemistry  | Protein         | PP=PC   |                                     |
|                 |         | Male<br>Sprague-<br>Dawley<br>Rat | Immunohistochemistry  | Protein         | PP=PC   | (Donner et al., 2007)               |
| Slc21a1         | Oatp1a1 | Male<br>Sprague-<br>Dawley<br>Rat | Immunoblot/Isolated<br>hepatocytes enriched by<br>digitonin/collagenase<br>perfusion              | Protein         | PP=PC   | (Abu-<br>Zahra et<br>al., 2000)     |
|                 |         | Male<br>Sprague-<br>Dawley<br>Rat | Quantitative PCR/<br>Isolated hepatocytes by<br>ante- or retrograde<br>perfusion with digitonin   | mRNA            | PP=PC<br>*mRNA<br>expression tends<br>to be greater in<br>PC region<br>although there is<br>no statistical<br>significance. | (Baier et<br>al., 2006)             |
|                 |         |                                   | Immunohistochemistry  | Protein         | PP=PC<br>*Protein<br>expression is<br>excluded in the<br>midzonal area.   |                                     |
|                 |         | Male<br>Sprague-<br>Dawley<br>Rat | Immunohistochemistry  | Protein         | PP=PC   | (Donner et<br>al., 2007)            |
| Slc21a10        | Oatp1b2 | Male<br>Sprague-<br>Dawley<br>Rat | Immunohistochemistry  | Protein         | PP <pc< td=""><td>(Donner et<br/>al., 2007)</td></pc<>  | (Donner et<br>al., 2007)            |
| Slc22a1         | Oct1    | Rat                               | Immunohistochemistry  | Protein         | PP <pc< td=""><td>(Meyer-<br/>Wentrup et<br/>al., 1998)</td></pc<>  | (Meyer-<br>Wentrup et<br>al., 1998) |
| Slc22a7         | Oat2    | Rat                               | Quantitative PCR/Laser capture microdissection  | mRNA            | PP=PC   | (Fork et al., 2011)                 |
| Abc transp      | orter   |                                   |   |                 |   |                                     |
| Abcb11          | Bsep    | Male<br>Sprague-                  | Quantitative<br>PCR/Isolated<br>hepatocytes by ante- or   | mRNA            | PP <pc< td=""><td>(Baier et al., 2006)</td></pc<>   | (Baier et al., 2006)                |

|         |         | Dawley<br>Rat                          | retrograde perfusion<br>with digitonin   |                 |   |                                 |
|---------|---------|--|--|-----------------|---|---------------------------------|
|         |         | Tut                                    | Immunohistochemistry   | Protein         | PP <pc<br>* Predominant<br/>pericentral<br/>cytoplasmatic<br/>staining.</pc<br> |                                 |
|         |         | Male<br>Sprague-<br>Dawley<br>Rat      | Immunohistochemistry   | Protein         | PP=PC   | (Donner et al., 2007)           |
|         |         | Male<br>Wistar<br>Rat                  | Immunohistochemistry   | Protein         | PP>PC   | (Micuda et al., 2008)           |
| Abcc2   | Mrp2    | Male<br>Sprague-<br>Dawley<br>Rat      | Quantitative PCR/<br>Isolated hepatocytes by<br>ante- or retrograde<br>perfusion with digitonin        | mRNA            | PP=PC   | (Baier et<br>al., 2006)         |
|         |         |  | Immunohistochemistry   | Protein         | PP=PC   |                                 |
| Abcc4   | Mrp4    | Male<br>Sprague-<br>Dawley<br>Rat      | Immunohistochemistry   | Protein         | PP=PC   | (Donner et<br>al., 2007)        |
| Enzyme  |         |  |  |                 |   |                                 |
| Cyp2c29 | Cyp2c29 | Male<br>C3H/He<br>Mouse                | Microarray/Isolated<br>hepatocytes enriched by<br>digitonin/collagenase<br>perfusion                   | mRNA            | PP <pc< td=""><td>(Braeunin<br/>g et al.,<br/>2006)</td></pc<>                  | (Braeunin<br>g et al.,<br>2006) |
| Cyp2e1  | Cyp2e1  | Male<br>C3H/He<br>Mouse                | Quantitative<br>PCR/Isolated<br>hepatocytes enriched by<br>digitonin/collagenase<br>perfusion          | mRNA            | PP <pc< td=""><td>(Braeunin<br/>g et al.,<br/>2006)</td></pc<>                  | (Braeunin<br>g et al.,<br>2006) |
|         |         | Male<br>Alko<br>mixed<br>strain<br>Rat | Immunohistochemistry   | Protein         | PP <pc< td=""><td>(Buhler et<br/>al., 1992)</td></pc<>                          | (Buhler et<br>al., 1992)        |
| Other   |         |  |  |                 |   |                                 |
| Glul    | GS      | Mouse<br>C3H/He<br>Mouse               | Microarray and<br>Immunoblot/Isolated<br>hepatocytes enriched by<br>digitonin/collagenase<br>perfusion | mRNA<br>Protein | PP <pc<br>PP<pc< td=""><td>(Braeunin<br/>g et al.,<br/>2006)</td></pc<></pc<br> | (Braeunin<br>g et al.,<br>2006) |

Protein or mRNA expressions of transporters and metabolizing enzymes in liver PP or PC regions are summarized according to the previous reports. PP=PC: Even/Homogenous distribution in PP and PC regions, PP>PC: PP region-predominant distribution, PP<PC: PC region-predominant distribution

## DMD#79244 References

- Abu-Zahra TN, Wolkoff AW, Kim RB, and Pang KS (2000) Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. *Drug Metab Dispos* 28:801-806.
- Baier PK, Hempel S, Waldvogel B, and Baumgartner U (2006) Zonation of hepatic bile salt transporters. *Dig Dis Sci* **51:**587-593.
- Braeuning A, Ittrich C, Kohle C, Hailfinger S, Bonin M, Buchmann A, and Schwarz M (2006)
  Differential gene expression in periportal and perivenous mouse hepatocytes. *FEBS J* 273:5051-5061.
- Buhler R, Lindros KO, Nordling A, Johansson I, and Ingelman-Sundberg M (1992) Zonation of cytochrome P450 isozyme expression and induction in rat liver. *Eur J Biochem* **204**:407-412.
- Donner MG, Schumacher S, Warskulat U, Heinemann J, and Haussinger D (2007) Obstructive cholestasis induces TNF-alpha- and IL-1 -mediated periportal downregulation of Bsep and zonal regulation of Ntcp, Oatp1a4, and Oatp1b2. *Am J Physiol Gastrointest Liver Physiol* **293:**G1134-1146.
- Fork C, Bauer T, Golz S, Geerts A, Weiland J, Del Turco D, Schomig E, and Grundemann D (2011) OAT2 catalyses efflux of glutamate and uptake of orotic acid. *Biochem J* **436**:305-312.
- Meyer-Wentrup F, Karbach U, Gorboulev V, Arndt P, and Koepsell H (1998) Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. *Biochem Biophys Res Commun* **248**:673-678.
- Micuda S, Fuksa L, Brcakova E, Osterreicher J, Cermanova J, Cibicek N, Mokry J, Staud F, and Martinkova J (2008) Zonation of multidrug resistance-associated protein 2 in rat liver after induction with dexamethasone. *J Gastroenterol Hepatol* **23**:e225-230.

## DMD#79244



**Supplemental Figure S1** Uneven distribution of SR-101 in the liver acinus of mice at 30 min (A) or 90 min (B and C) after intravenous injection of SR-101. There are distinct regions strongly positive for SR-101 and either negative or weakly positive for SR-101, respectively. Scale bar:  $50 \mu m$ .



**Supplemental Figure S2** A comparison of protein expression levels of transporters/receptors (A) and metabolizing enzymes (B) in the SR-101(+) and SR-101(-) liver regions of mice intravenously injected with SR-101. The solid line passing through the origin represents the line of identity, and the broken lines represent 2-fold differences. A; 1. Oatp1a1, 2. Mct1, 3. Slc22a18, 4. Ntcp, 5. Ent1, 6. Oatp1b2, 7. FcRn, 8. Bcrp, 9. Mrp6, 10. Bsep, 11. Oct1, 12. Mrp2, 13. Abcb4, 14. Abcg5, 15. 4F2hc, 16. Oat2, 17. Mrp4, 18. Oatp1a4. B; 1. Cyp2c29, 2. Cyp2e1, 3. Ugt1a9, 4. Cyp3a11, 5. Ugt2b3, 6. Ugt1a1, 7. NADPH-CPR, 8. Cyp2d22, 9. Cyp51a1, 10. Cyp8b1. Each point represents the mean $\pm$ S.D. (n=3) in three independent analyses. U.L.Q; under the limit of quantification. \*\*p<0.01, significantly different between the SR-101(+) and SR-101(-) regions. The individual values are shown in Table 1.



**Supplemental Figure S3** Mouse Oatp2b1 mediates SR-101 uptake. (A) Representative fluorescence images of SR-101 in control HEK293 cells (Control/HEK293; A1 and A2) and mouse Oatp2b1-overexpressing HEK293 cells (Oatp2b1/HEK293; A3 and A4). Scale bars: 100  $\mu$ m. (B) Comparison of the SR-101 uptake amounts in Control/HEK293 cells (open column) and Oatp2b1/HEK293 cells (closed column). Each column represents the mean±S.E.M (n=4). \*\*p<0.01, significantly different between Oatp2b1/HEK293 and Control/HEK293 cells.



**Supplemental Figure S4** A comparison of protein expression levels of transporters, normalized by the level of 4F2hc, in the plasma membrane fractions of total mouse liver and laser-microdissected samples from frozen mouse liver sections. The data on plasma membranes are taken from the previous report (Miura et al., 2017). The data on the frozen liver sections are taken from Table 1. Each point represents the mean value of each transporter protein level divided by that of 4F2hc. The solid line passing through the origin represents the line of identity, and the broken lines represent 2-fold differences. The numbers near the circles identify the transporter: 1 Oatp1a1, 2 Na<sup>+</sup>, K<sup>+</sup>- ATPase, 3 Mct1, 4 Ntcp, 5 Ent1, 6 Oatp1b2, 7 Bcrp, 8 Mrp6, 9 Bsep, 10 Mrp2, 11 Abcb4, 12 Abcg5, 13 4F2hc, 14 Mrp4.

## Reference

Miura T, Tachikawa M, Ohtsuka H, Fukase K, Nakayama S, Sakata N, Motoi F, Naitoh T, Katayose Y, Uchida Y, Ohtsuki S, Terasaki T, Unno M (2017) Application of quantitative targeted absolute proteomics to profile protein expression changes of hepatic transporters and metabolizing enzymes during cholic acid-promoted liver regeneration. *J Pharm Sci* **106**:2499-2508.